Clinical trial · Observational
Tumor-Infiltrating Lymphocytes in Endometrial Cancer
Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Correlations With Tumor Grade, Stage, and Subcellular CD133, WNT-1, and mTOR Expression
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Endometrial cancer (EC) is a leading cancer among women globally. The tumor microenvironment in EC is characterized by complex interactions between cancer cells and immune components. Among these proteins, CD133, WNT-1, and mTOR have emerged as key molecular markers with potential prognostic and therapeutic implications in EC. Understanding the association between these molecular alterations and the immune contexture of EC can provide valuable insights into EC biology and lead to the identification of novel therapeutic targets. In this study, the spatial organization of tumor-infiltrating lymphocytes (TILs) in EC and their correlations with tumor grade, stage, and subcellular CD133, WNT-1, and mTOR expression were investigated. Artificial intelligence-assisted image analysis was performed to quantify TIL metrics, including TIL percentage, grey level co-occurrence matrix (GLCM M1 and M2) parameters, and fractal dimension (FD).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrium Cancer | — | UNRESOLVED | — |
| Tumor Infiltration | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fractal dimension (FD) | Diagnostic Test | — | UNRESOLVED |
| Grey level co-occurrence matrix (GLCM) | Diagnostic Test | — | UNRESOLVED |
| Tumor-infliltrating lymphocyte (TIL) percentage | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Low-grade Endometrial Cancer
- description
- Histological grade G1 and G2
- interventionNames
- Diagnostic Test: Tumor-infliltrating lymphocyte (TIL) percentage
- Diagnostic Test: Grey level co-occurrence matrix (GLCM)
- Diagnostic Test: Fractal dimension (FD)
- label
- High-grade Endometrial Cancer
- description
- Histological grade G3
- interventionNames
- Diagnostic Test: Tumor-infliltrating lymphocyte (TIL) percentage
- Diagnostic Test: Grey level co-occurrence matrix (GLCM)
- Diagnostic Test: Fractal dimension (FD)
Primary outcomes (4)
- measure
- TIL percentage [%]
- timeFrame
- up to 6 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * confirmed diagnosis of EC * adequate quality of archival material * absence of prior neoadjuvant treatment * complete medical documentation Exclusion Criteria: * none
References
Publications (0)
Data not yet available